Patent intelligence · US
US 9034347
Drug delivery system and method for the treatment of neuro-degenerative disease
Drug delivery system and method for the treatment of neuro-degenerative disease
Patent details — US 9034347
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 19, 2015
- Expiration
- May 14, 2035
- Applicant
- Arphios Corporation
- Claims
- 5
- CPC classes
- A61K, A61K31/365, A61K9/16, A61K9/4858
Quick answer
US 9034347 (Drug delivery system and method for the treatment of neuro-degenerative disease) is held by Arphios Corporation. Status: granted. Granted May 19, 2015. Expires May 14, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Arphios Corporation
- Grant date
- Expiration
- Claims
- 5
- CPC classes
- A61K, A61K31/365, A61K9/16, A61K9/4858, A61K9/5153
More from Arphios Corporation
Related pharmaceutical patents in our USPTO index.
-
US 11926828
Methods for treating aging and skin disorders using nucleic acids targeting TYR or MMP1
granted -
US 11639359
Bryoid compositions, methods of making and use thereof
granted -
US 11584933
RNA interference in ocular indications
granted -
US 11396654
Neutral nanotransporters
granted -
US 11279934
Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
granted -
US 11254940
Inhibition of MAP4K4 through RNAi
granted -
US 11234932
Combination HIV therapeutic
granted -
US 11118178
Reduced size self-delivering RNAI compounds
granted
Frequently asked questions
What is US patent 9034347?
US 9034347 (Drug delivery system and method for the treatment of neuro-degenerative disease) is held by Arphios Corporation. Status: granted. Granted May 19, 2015. Expires May 14, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9034347?
Arphios Corporation is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 39 pharmaceutical patents for this assignee.
When does US 9034347 expire?
Our index shows an expiration date of May 14, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.